Alpha Tau Medical Ltd./$DRTS

1D1W1MYTD1Y5YMAX

About Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
Ticker
$DRTS
Sector
Health
Primary listing
NASDAQ
Employees
121
Headquarters
Jerusalem, Israel
Website
www.alphatau.com

DRTS Metrics

BasicAdvanced
$1.3B
-
-$1.05
1.18
-

Bulls say / Bears say

Alpha DaRT combined with pembrolizumab produced a 100% objective response rate and 18.2-month median overall survival in evaluable patients with advanced head and neck cancer. The study passed its pre-specified success threshold, supporting the case that local alpha radiation may improve an established immunotherapy. (GlobeNewswire)
The FDA allowed Alpha Tau to complete the REGAIN glioblastoma trial and add two US sites after reviewing interim safety data. The first three patients showed 100% local disease control and a 67% complete response rate, creating a potentially valuable catalyst in a cancer with few effective treatments. (Alpha Tau Medical)
The Tolmar agreement gives Alpha Tau a commercial partner for US prostate cancer, $20 million of equity at a 25% premium, $15 million towards manufacturing and potential development and commercial milestones. Together with $104.8 million of cash and deposits at 30 June, this improves funding and gives the platform a clearer route towards commercialisation. (Alpha Tau Medical, BioSpace)
Alpha DaRT is still pre-commercial in the US. The company has begun a modular PMA submission, but it still needs successful registrational evidence, FDA authorisation and the manufacturing, sales and logistics infrastructure required to launch a product. (StockTitan, Tickerguard)
Alpha Tau remains loss-making and expects substantial spending for several years. Although management says its $104.8 million resource base should fund operations for at least two years, delays, larger trials or commercial preparation could force another fundraise and dilute shareholders. (StockTitan)
The investment case rests on early signals from small, open-label or single-arm studies, while the shares already reflect strong expectations despite essentially no product revenue. Larger readouts from skin, pancreatic and brain-cancer programmes therefore carry meaningful downside if the initial results fail to hold at scale. (Seeking Alpha, Simply Wall St)
Data summarised monthly by Lightyear AI. Last updated on 19 Sept 2026.

Funds containing DRTS

AllUSDEURGBP
Funds
Fund name
Fund size
$DRTS weighting
iShares MSCI World Small Cap$WSML
$9B0.01%
iShares MSCI World Small Cap€IUSN
€7.8B0.01%
iShares MSCI World Small Cap£WLDS
£6.7B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.